A new biomarker identified for Huntington's disease (HD) aids in evaluating the effectiveness of the treatment and can also postpone the onset of the disease, reveals a new study.
The study, led by researchers at Boston University School of Medicine (BUSM) in collaboration with the PREDICT-HD study coordinated by colleagues at the University of Iowa Carver College of Medicine, appears in the journal Neurology.
Drug Deutetrabenazine Helps Control Sudden Movements of Huntington Disease
To control a prominent symptom of Huntington disease, chorea, researchers evaluated the efficacy and safety of the drug deutetrabenazine.
Advertisement
‘Novel biomarker developed for treating Huntington's disease (HD) can reduce the levels of the microRNAs and postpones the onset of the disease.’
Tweet it Now
HD is a fatal, inherited neurological disease that usually manifests between 30 and 50 years of age. The disease is caused by a genetic defect that is passed from parent to child in the Huntington gene. Having too many repeated elements in the gene sequence causes the disease and an increasing number of repeats leads to earlier onset and increased severity of the condition.
The research team studied cerebrospinal fluid (CSF) from 30 individuals who carry the mutation that causes HD, but who were not yet showing symptoms. They were able to identify altered levels of a molecule (also called microRNA) in individuals as much as twenty years before the expected onset of symptoms.
![Mutation in the Huntingtin Gene Leads to Huntington Disease]( "Mutation in the Huntingtin Gene Leads to Huntington Disease")
Huntington disease (HD) is caused by a mutation in the huntingtin gene (htt) and is an incurable neurodegenerative disease.
"The most interesting finding was that the levels of the microRNAs begin to increase many years before the individual shows symptoms and continue to increase as disease onset approaches. Clinical trials for new HD treatments that may reduce the levels of the microRNAs suggest that these treatments may postpone the onset of the disease," explained corresponding author Richard H. Myers, PhD, professor of neurology and Director of the Genome Science Institute at BUSM.
According to the researchers these findings may represent a more effective way to tell whether or not HD treatments may postpone the disease before it begins.
"By evaluating microRNAs in the CSF, it may become feasible to perform these trials in people who are HD gene carriers, but who do not yet show symptoms, by giving evidence for which trials may postpone onset and provide more healthy years of life," added Myers.
These findings also suggest that other microRNAs may also be important markers of severity for other neurological diseases such as Parkinson's and Alzheimer's.
Source: Eurekalert
Mutation in the Huntingtin Gene Leads to Huntington Disease
Huntington disease (HD) is caused by a mutation in the huntingtin gene (htt) and is an incurable neurodegenerative disease.
Advertisement
"The most interesting finding was that the levels of the microRNAs begin to increase many years before the individual shows symptoms and continue to increase as disease onset approaches. Clinical trials for new HD treatments that may reduce the levels of the microRNAs suggest that these treatments may postpone the onset of the disease," explained corresponding author Richard H. Myers, PhD, professor of neurology and Director of the Genome Science Institute at BUSM.
According to the researchers these findings may represent a more effective way to tell whether or not HD treatments may postpone the disease before it begins.
"By evaluating microRNAs in the CSF, it may become feasible to perform these trials in people who are HD gene carriers, but who do not yet show symptoms, by giving evidence for which trials may postpone onset and provide more healthy years of life," added Myers.
These findings also suggest that other microRNAs may also be important markers of severity for other neurological diseases such as Parkinson's and Alzheimer's.
Source: Eurekalert
Onset of Huntington Disease Predicted by Striatal Brain Volume
Huntington disease (HD) is caused by a defect on chromosome four and is an inherited neurodegenerative disorder.
Advertisement
 New Test Helps to Streamline Testing for Huntington DiseaseTo streamline genetic testing for Huntington Disease (HD), a new test may help by generating accurate results, avoiding unnecessary additional testing and improving turnaround time. | Advertisement
|
Advertisement
Latest Mental Health News
Research suggests that loneliness can create confusion between genuine friends and cherished fictional characters, activating the same brain area.
Schizophrenic patients have a genetic link to increased cardiovascular risk factors, especially smoking and body mass index.
Mental health issues such as anxiety and depression could be precursors to multiple sclerosis (MS), even before the classic MS symptoms appear.
Studying brain circuits tied to PTSD's progression from acute to chronic states is vital for grasping its pathophysiology and crafting targeted treatments.
Older adults with COPD were roughly twice as likely to develop depression if they faced functional limitations.
